Maverick Capital’s Myriad Genetics MYGN Stock Holding History

Maverick Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-190,720	Closed	-$3.18M	–	144
2016 Q4	$3.18M	Buy	190,720 +38,670	+25%	+$700K	0.04%	66
2016 Q3	$3.13M	Buy	152,050 +58,180	+62%	+$1.48M	0.04%	65
2016 Q2	$2.87M	Buy	+93,870	New	+$3.26M	0.04%	65

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Maverick Capital's MYGN Position: Q1 2017 in Review

Maverick Capital sold out of Myriad Genetics (MYGN) in Q1 2017, closing a stake of 190,720 shares — an estimated $3.18M sold.

Maverick Capital first reported a position in MYGN in Q2 2016 and held it in 3 quarters. The position peaked at $3.18M in Q4 2016. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2017.

Maverick Capital reported no remaining Myriad Genetics position as of Q1 2017 after selling out during the quarter.
Maverick Capital sold 190,720 Myriad Genetics shares in Q1 2017, an estimated $3.18M.
Maverick Capital first reported a position in Myriad Genetics in Q2 2016 and held it in 3 quarters.
Maverick Capital's Myriad Genetics position peaked at $3.18M in Q4 2016.
233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2017.

Based on Maverick Capital's 13F filing for Q1 2017, filed 15 May 2017.